Mangalam Drugs And Organics Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mangalam Drugs and Organics Limited reported a massive turnaround from profit to loss for FY 2025-26. Standalone revenue declined to Rs. 23,213 lakhs from Rs. 31,758 lakhs in the previous year, representing approximately 27% revenue decline. The company posted a net loss of Rs. 4,381 lakhs compared to a net profit of Rs. 692 lakhs in FY 2024-25. EPS dropped to Rs. (27.68) from Rs. 4.37. Consolidated net loss stood at Rs. 4,440 lakhs. Operating cash flow reduced significantly to Rs. 416 lakhs from Rs. 4,276 lakhs in the prior year. Borrowings increased substantially with current borrowings rising from Rs. 7,095 lakhs to Rs. 9,456 lakhs. The auditor issued a clean (unmodified) opinion. A merger scheme involving subsidiary Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited is pending NCLT approval with hearing scheduled for June 2026.
The company experienced severe financial deterioration with revenue dropping 27% and swinging to a large loss. Increased debt and sharply reduced operating cash flow raise concerns about financial health. Shareholders should monitor the pending merger approval and cost control measures.